Previous studies suggest that RRM1 and RRM2 could predict the prognosis of patients treated with gemcitabine, as they report that relatively high expression of these two genes in pancreatic cancer is associated with a poor prognosis, and patients who do not benefit from gemcitabine treatment tend to have elevated RRM1 and RRM2 expression [42, 43]. This evidence concerns the gene RRM1 and familial pancreatic carcinoma.